Iminosugars past, present and future: medicines for tomorrow.

Iminosugars comprise the most attractive class of carbohydrate mimetics reported to date and are ideally positioned to take advantage of our increasing understanding of glycobiology in the search for new medicines. First-generation iminosugar drugs suffered from lack of adequate selectivity, resulting in considerable side-effects in the clinic. Current efforts directed towards second-generation compounds, encompassing a much greater range of structures and addressing a wider selection of biochemical targets, are enabling the identification and development of suitable candidates that benefit from improved activity and selectivity. Furthermore, second-generation compounds can address a variety of established targets that have previously proved refractory to other compound classes. This review focuses on the breadth of opportunities provided by second-generation leads from iminosugars (Seglins™).

[1]  D. Burton,et al.  N-Butyldeoxynojirimycin is a broadly effective anti-HIV therapy significantly enhanced by targeted liposome delivery , 2008, AIDS.

[2]  A. Watson,et al.  Iminosugars from Baphia nitida Lodd. , 2008, Phytochemistry.

[3]  A. Ballabio,et al.  Pharmacological Enhancement of Mutated α-Glucosidase Activity in Fibroblasts from Patients with Pompe Disease. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  P. Sharma,et al.  Scale-Up Synthesis of Swainsonine: A Potent α-Mannosidase II Inhibitor† , 2008 .

[5]  P. Compain,et al.  Tactics and strategies for the synthesis of iminosugar C-glycosides: a review , 2009 .

[6]  S. Inouye,et al.  The structure of nojirimycin, a piperidinose sugar antibiotic. , 1966, The Journal of antibiotics.

[7]  Chung-Yi Wu,et al.  Glycan array: a powerful tool for glycomics studies , 2009, Expert review of proteomics.

[8]  Raymond A. Dwek,et al.  Glycobiology: Toward Understanding the Function of Sugars. , 1996, Chemical reviews.

[9]  H. Overkleeft,et al.  Dual-action lipophilic iminosugar improves glycemic control in obese rodents by reduction of visceral glycosphingolipids and buffering of carbohydrate assimilation. , 2010, Journal of medicinal chemistry.

[10]  L. Cipolla,et al.  Combinatorial approaches to iminosugars as glycosidase and glycosyltransferase inhibitors. , 2006, Combinatorial chemistry & high throughput screening.

[11]  Naoyuki Taniguchi,et al.  Aberrant expression of N-acetylglucosaminyltransferase-IVa and IVb (GnT-IVa and b) in pancreatic cancer. , 2006, Biochemical and biophysical research communications.

[12]  M. Lotz,et al.  Hexosaminidase inhibitors as new drug candidates for the therapy of osteoarthritis. , 2001, Chemistry & biology.

[13]  Koichiro Yoshino,et al.  CB-12181, a new azasugar-based matrix metalloproteinase/tumor necrosis factor-alpha converting enzyme inhibitor, inhibits vascular endothelial growth factor-induced angiogenesis in vitro and retinal neovascularization in vivo. , 2009, Current Neurovascular Research.

[14]  Li-he Zhang,et al.  Rapid Synthesis of Iminosugar Derivatives for Cell‐Based In Situ Screening: Discovery of “Hit” Compounds with Anticancer Activity , 2007, ChemMedChem.

[15]  O. Reiser,et al.  Stereoselective Synthesis of Swainsonines from Pyridines , 2005 .

[16]  L. Presta,et al.  Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.

[17]  R. Clarkson,et al.  Large scale synthesis of the acetonides of l-glucuronolactone and of l-glucose: easy access to l-sugar chirons , 2009 .

[18]  Mattie S. M. Timmer,et al.  Recent Developments in the Synthesis of Pyrrolidine‐Containing Iminosugars , 2010 .

[19]  P. D. Lilley,et al.  Homonojirimycin isomers and N-alkylated homonojirimycins: structural and conformational basis of inhibition of glycosidases. , 1998, Journal of medicinal chemistry.

[20]  R. Lachmann.  Miglustat: substrate reduction therapy for glycosphingolipid lysosomal storage disorders. , 2006, Drugs of today.

[21]  Tibor Kozár,et al.  Glycan and lectin microarrays for glycomics and medicinal applications , 2010, Medicinal research reviews.

[22]  Annalisa Guaragna,et al.  Glycomimetics at the mirror: medicinal chemistry of L-iminosugars. , 2009, Current medicinal chemistry.

[23]  Jian‐Qiang Fan.  Iminosugars as Active‐Site‐Specific Chaperones for the Treatment of Lysosomal Storage Disorders , 2008 .

[24]  J. Dubuisson,et al.  Involvement of Endoplasmic Reticulum Chaperones in the Folding of Hepatitis C Virus Glycoproteins , 1998, Journal of Virology.

[25]  F. Nicotra,et al.  General Strategies for the Synthesis of Iminosugars and New Approaches Towards Iminosugar Libraries , 2007 .

[26]  R. Spiro.  Protein glycosylation: nature, distribution, enzymatic formation, and disease implications of glycopeptide bonds. , 2002, Glycobiology.

[27]  K. Mansfield,et al.  Natural iminosugar derivatives of 1-deoxynojirimycin inhibit glycosylation of hepatitis viral envelope proteins. , 2007, Journal of microbiology.

[28]  J. E. Thomson,et al.  Iodine-mediated ring-closing iodoamination with concomitant N-debenzylation for the asymmetric synthesis of polyhydroxylated pyrrolidines , 2009 .

[29]  P. Smith,et al.  Synthesis of deoxymannojirimycin fagomine deoxynojirimycin 2-acetamido-1,5-imino-1,2,5-trideoxy-D-mannitol 2-acetamido-1,5-imino-1,2,5-trideoxy-D-glucitol 2S,3R,4R,5R-trihydroxypipecolic acid and 2S,3R,4R,5S-trihydroxypipecolic acid from methyl 3-O-benzyl-2,6-dideoxy-2,6-imino-α-D-mannofuranoside , 1987 .

[30]  F. Platt,et al.  Medicinal use of iminosugars , 2008 .

[31]  A. Elbein,et al.  Swainsonine: an inhibitor of glycoprotein processing. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[32]  S. Nishimura,et al.  Azasugar-based MMP/ADAM inhibitors as antipsoriatic agents. , 2004, Journal of medicinal chemistry.

[33]  N. Asano.  Naturally occurring iminosugars and related compounds: structure, distribution, and biological activity. , 2003, Current topics in medicinal chemistry.

[34]  R. Moriarty,et al.  Novel Imino Sugar Derivatives Demonstrate Potent Antiviral Activity against Flaviviruses , 2009, Antimicrobial Agents and Chemotherapy.

[35]  Lihua Yu,et al.  Suppression of FUT1/FUT4 expression by siRNA inhibits tumor growth. , 2008, Biochimica et biophysica acta.

[36]  V. Ranade.  Iminosugars-From Synthesis to Therapeutic Applications , 2009 .

[37]  M. Wormald,et al.  Cystic fibrosis and diabetes: isoLAB and isoDAB, enantiomeric carbon-branched pyrrolidine iminosugars , 2010 .

[38]  Benjamin G Davis,et al.  Glyco- and peptidomimetics from three-component Joullié-Ugi coupling show selective antiviral activity. , 2005, Journal of the American Chemical Society.

[39]  T. Aoyagi,et al.  Purification and characterization of a sialidase inhibitor, siastatin, produced by Streptomyces. , 1974, The Journal of antibiotics.

[40]  I. Izquierdo,et al.  Polyhydroxylated pyrrolizidines. Part 6 : A new and concise stereoselective synthesis of ( + )-casuarine and its 6,7-diepi isomer, from DMDP , 2005 .

[41]  T. Butters,et al.  Rational design and synthesis of highly potent pharmacological chaperones for treatment of N370S mutant Gaucher disease. , 2009, Journal of medicinal chemistry.

[42]  R. Dwek,et al.  Secretion of human hepatitis B virus is inhibited by the imino sugar N-butyldeoxynojirimycin. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[43]  L. Sorbera,et al.  Celgosivir: α-Glucosidase inhibitor anti-hepatitis C virus drug , 2005 .

[44]  J. Marth,et al.  Glycosylation in Cellular Mechanisms of Health and Disease , 2006, Cell.

[45]  Shui-Tein Chen,et al.  Synthesis of DMJ analogs with seven- and eight-membered iminocyclitols , 2007 .

[46]  R. Dwek,et al.  Inhibition of hepatitis B virus DNA replication by imino sugars without the inhibition of the DNA polymerase: Therapeutic implications , 2001, Hepatology.

[47]  R. Dwek,et al.  Looking glass inhibitors: efficient synthesis and biological evaluation of D-deoxyfuconojirimycin. , 2005, Carbohydrate research.

[48]  A. Varki,et al.  Biological roles of oligosaccharides: all of the theories are correct , 1993, Glycobiology.

[49]  Richard D. Cummings,et al.  The repertoire of glycan determinants in the human glycome. , 2009, Molecular bioSystems.

[50]  T. Donohoe,et al.  Synthesis of (+)-DGDP and (-)-7-epialexine. , 2008, Organic & biomolecular chemistry.

[51]  S. Kornfeld,et al.  Assembly of asparagine-linked oligosaccharides. , 1985, Annual review of biochemistry.

[52]  D. Loo,et al.  Imino Sugars Are Potent Agonists of the Human Glucose Sensor SGLT3 , 2007, Molecular Pharmacology.

[53]  Pere Clapés,et al.  D-fructose-6-phosphate aldolase in organic synthesis: cascade chemical-enzymatic preparation of sugar-related polyhydroxylated compounds. , 2009, Chemistry.

[54]  M. Bols,et al.  THE FIRST COMBINATORIAL LIBRARY OF AZASUGAR GLYCOSIDASE INHIBITORS , 1999 .

[55]  B. Winchester.  Iminosugars: from botanical curiosities to licensed drugs , 2009 .

[56]  K. Matsumoto,et al.  Inhibition of experimental metastasis by castanospermine in mice: blockage of two distinct stages of tumor colonization by oligosaccharide processing inhibitors. , 1986, Cancer research.

[57]  P. Compain,et al.  Design, synthesis and biological evaluation of iminosugar-based glycosyltransferase inhibitors. , 2003, Current topics in medicinal chemistry.

[58]  Kami Kim,et al.  Transition State Analogue Inhibitors of Purine Nucleoside Phosphorylase from Plasmodium falciparum * , 2002, The Journal of Biological Chemistry.

[59]  M. Wormald,et al.  Polyhydroxylated pyrrolidine and pyrrolizidine alkaloids from Hyancinthoides non-scripta and Scilla campanulata. , 1999, Carbohydrate research.

[60]  L. Agius,et al.  Diverse effects of two allosteric inhibitors on the phosphorylation state of glycogen phosphorylase in hepatocytes. , 2002, The Biochemical journal.

[61]  Toshihide Kobayashi,et al.  Molecular interaction of imino sugars with human alpha-galactosidase: Insight into the mechanism of complex formation and pharmacological chaperone action in Fabry disease. , 2009, Molecular genetics and metabolism.

[62]  T. Harris,et al.  Identification of swainsonine as a probable contributory mycotoxin in moldy forage mycotoxicoses , 1984, Applied and environmental microbiology.

[63]  L. Kiessling,et al.  Chemical approaches to glycobiology. , 2010, Annual review of biochemistry.

[64]  R. Hopkin,et al.  Fabry's disease , 2008, The Lancet.

[65]  A. Reuser,et al.  Pompe's disease , 2008, The Lancet.

[66]  Chen Wang,et al.  Looking glass inhibitors: scalable syntheses of DNJ, DMDP, and (3R)-3-hydroxy-l-bulgecinine from d-glucuronolactone and of l-DNJ, l-DMDP, and (3S)-3-hydroxy-d-bulgecinine from l-glucuronolactone. DMDP inhibits β-glucosidases and β-galactosidases whereas l-DMDP is a potent and specific inhibitor of α , 2010 .

[67]  H. Ploegh,et al.  Interference with HIV-induced syncytium formation and viral infectivity by inhibitors of trimming glucosidase , 1987, Nature.

[68]  Carolyn R. Bertozzi,et al.  Essentials of Glycobiology , 1999 .

[69]  H. Kajiyama,et al.  High expression of N-acetylglucosaminyltransferase V in mucinous tumors of the ovary. , 2009, Oncology reports.

[70]  W. Cornell,et al.  Discovery of potent, selective, and orally active carboxylic acid based inhibitors of matrix metalloproteinase-13. , 2009, Journal of medicinal chemistry.

[71]  R. Dwek,et al.  Cellular effects of deoxynojirimycin analogues: uptake, retention and inhibition of glycosphingolipid biosynthesis. , 2004, The Biochemical journal.

[72]  G. Besra,et al.  Synthesis of the naringinase inhibitors l-swainsonine and related 6-C-methyl-l-swainsonine analogues: (6R)-C-methyl-l-swainsonine is a more potent inhibitor of l-rhamnosidase by an order of magnitude than l-swainsonine , 2008 .

[73]  J. Hoffman,et al.  Mutation analysis of B3GALTL in Peters Plus syndrome , 2008, American journal of medical genetics. Part A.

[74]  O. Morand,et al.  The pharmacokinetics and tissue distribution of the glucosylceramide synthase inhibitor miglustat in the rat , 2007, Xenobiotica; the fate of foreign compounds in biological systems.

[75]  J. E. Wraith,et al.  New therapies in the management of Niemann-Pick type C disease: clinical utility of miglustat , 2009 .

[76]  René Ranzinger,et al.  Exploring the structural diversity of mammalian carbohydrates ("glycospace") by statistical databank analysis. , 2007, ACS chemical biology.

[77]  Hudson H. Freeze,et al.  Genetic defects in the human glycome , 2006, Nature Reviews Genetics.

[78]  K. Yasuda,et al.  Polyhydroxylated alkaloids isolated from mulberry trees (Morusalba L.) and silkworms (Bombyx mori L.). , 2001, Journal of agricultural and food chemistry.

[79]  J. M. Aerts,et al.  Inhibition of Glycosphingolipid Synthesis Induces a Profound Reduction of Plasma Cholesterol and Inhibits Atherosclerosis Development in APOE*3 Leiden and Low-Density Lipoprotein Receptor−/− Mice , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[80]  Haibing Guo,et al.  DE NOVO ASYMMETRIC APPROACH TO 8a-epi-SWAINSONINE , 2009 .

[81]  D. Rowlands,et al.  Genotype‐dependent sensitivity of hepatitis C virus to inhibitors of the p7 ion channel , 2008, Hepatology.

[82]  A. Watson,et al.  Polyhydroxylated alkaloids -- natural occurrence and therapeutic applications. , 2001, Phytochemistry.

[83]  A. Sacchetti,et al.  A chemoenzymatic-RCM strategy for the enantioselective synthesis of new dihydroxylated 5-hydroxymethyl-indolizidines and 6-hydroxymethyl-quinolizidines , 2007 .

[84]  R. Janzer,et al.  Functionalized pyrrolidine inhibitors of human type II alpha-mannosidases as anti-cancer agents: optimizing the fit to the active site. , 2008, Bioorganic & medicinal chemistry.

[85]  C. Mandal,et al.  Elevated mRNA level of hST6Gal I and hST3Gal V positively correlates with the high risk of pediatric acute leukemia. , 2010, Leukemia research.

[86]  T. Andresen,et al.  A concise synthesis of castanospermine by the use of a transannular cyclization. , 2009, The Journal of organic chemistry.

[87]  N. Callewaert,et al.  Glycome profiling using modern glycomics technology: technical aspects and applications , 2010, Biological chemistry.

[88]  S. Denmark,et al.  Synthesis of (+)-casuarine. , 2000, The Journal of organic chemistry.

[89]  Paul W Smith,et al.  Inhibition of HIV replication by amino‐sugar derivatives , 1988, FEBS letters.

[90]  P. Lebecque,et al.  Airway delivery of low-dose miglustat normalizes nasal potential difference in F508del cystic fibrosis mice. , 2009, American journal of respiratory and critical care medicine.

[91]  G. Fleet,et al.  Looking glass inhibitors: synthesis of a potent naringinase inhibitor l-DIM [1,4-dideoxy-1,4-imino-l-mannitol], the enantiomer of DIM [1,4-dideoxy-1,4-imino-d-mannitol] a potent α-d-mannosidase inhibitor , 2007 .